Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Portfolio Pulse from Benzinga Insights
Rhythm Pharmaceuticals (NASDAQ:RYTM) has received 7 analyst ratings in the past quarter, with a consensus 12-month price target of $48.14, up from $38.86. Analysts from Goldman Sachs, Needham, Morgan Stanley, and Wells Fargo have raised their price targets, reflecting a bullish sentiment. The company's financials show a significant revenue growth rate of 425.3% and a high net margin of -196.25%, but a lower ROA of -13.3%. RYTM is engaged in developing therapies for rare diseases and obesity caused by MC4 pathway deficiencies.
January 25, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have raised price targets for Rhythm Pharmaceuticals, indicating a bullish outlook. The company's strong revenue growth and focus on rare diseases contribute to positive sentiment.
The unanimous raising of price targets by analysts from reputable firms such as Goldman Sachs and Morgan Stanley suggests a strong bullish sentiment for RYTM. The significant revenue growth rate and the company's niche in rare disease therapies further support the positive outlook. However, the high net margin loss and lower ROA indicate some financial challenges, which slightly moderates the confidence score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100